Enanta Pharma (ENTA) Misses Q4 EPS by 20c

Enanta Pharma (NASDAQ: ENTA) reported Q4 EPS of ($1.36), $0.20 worse than the analyst estimate of ($1.16). Revenue for the quarter came in at $14.61 million versus the consensus estimate of $17.99 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Invesco Mortgage Capital declares $0.12 monthly dividend for June 2026
• TechCreate Group faces NYSE American delisting proceedings